Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions

Dabigatran, rivaroxaban, apixaban, and edoxaban are direct oral anticoagulants (DOACs) that are increasingly used worldwide. Taking into account their widespread use for the prevention of thromboembolism in cardiology, neurology, orthopedics, and coronavirus disease 2019 (COVID 19) as well as their...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Natalia A. Shnayder, Marina M. Petrova, Pavel A. Shesternya, Alina V. Savinova, Elena N. Bochanova, Olga V. Zimnitskaya, Elena A. Pozhilenkova, Regina F. Nasyrova
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2021-04-01
Serie:	Biomedicines
Soggetti:	pharmacokinetics pharmacogenetics dabigatran rivaroxaban apixaban edoxaban
Accesso online:	https://www.mdpi.com/2227-9059/9/5/451
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!